Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGF-1 in Peripheral Arterial Disease Patients With Intermittent Claudication
NCT00424866Phase 2Not yet recruiting
- Sponsor
- Venturis Therapeutics
- Start
- Oct 2028
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
A Phase 2 trial of fibroblast growth factor 1 in Peripheral Arterial Disease (PAD), sponsored by Venturis Therapeutics. Planned start Oct 2028; status: not yet recruiting.
02
Drugs
fibroblast growth factor 1
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT00424866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424866.